Republicans Seek Documents, Schedule Hearing Related To FDA’s Response To Baby-Formula Shortage
House Republicans are reportedly speeding up their scrutiny of the FDA and the White House's handling of the baby formula shortage last year.
FDA Seeks 10% Increase In Biden’s FY 2024 Budget, Proposes Enhancing Regulatory Authorities
The FDA has requested $7.2 billion as part of the president’s fiscal year 2024 budget, $128.2 million of which the…
Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
Data Shows Abbott’s TriClip System Superior To Other Medical Therapy In Heart Valve Disorder
Abbott Laboratories (NYSE:ABT) announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a minimally invasive device designed specifically for…
Abbott Labs Announced New Five-year Data Presented At American College Of Cardiology Scientific Sessions And Simultaneously Published In The New England Journal Of Medicine Reinforce The Long-term Safety And Effectiveness Of Mitraclip For Treating Seco…
Abbott (NYSE: ABT) today announced late-breaking data for MitraClip™, the leading therapy to treat leaky valves in people with mitral regurgitation (MR), that demonstrate long-term benefits of the device in patients battling heart failure.
How Is The Market Feeling About Abbott Laboratories?
Abbott Laboratories's (NYSE:ABT) short percent of float has risen 11.43% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.78% of all regular shares that are available for trading.
What Does Apple Have To Do With DexCom Stock Trading Lower?
DexCom shares (NASDAQ: DXCM) are trading lower on Wednesday following a report that Apple Inc (NASDAQ: AAPL) is making progress on no-prick glucose tracking for its Watch.
Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M
Abbott Laboratories (NYSE:ABT) agrees to acquire Cardiovascular Systems Inc (NASDAQ:CSII) for $20/share for an equity value of approximately $890 million. CSI offers…
Abbott Reported Earlier It Will Acquire Cardiovascular Systems For $20/Share
Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.